Small-molecule antiviral β-d-n4-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance

Journal of Virology

Volumn 93, Issue 24, 2019, Pages

  Agostini, Maria L ^a   Pruijssers, Andrea J ^a   Chappell, James D ^a   Gribble, Jennifer ^a   Lu, Xiaotao ^a   Andres, Erica L ^a   Bluemling, Gregory R ^b   Lockwood, Mark A ^b   Sheahan, Timothy P ^c   Sims, Amy C ^c   Natchus, Michael G ^b   Saindane, Manohar ^b   Kolykhalov, Alexander A ^b   Painter, George R ^b,d   Baric, Ralph S ^c   Denison, Mark R ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c University of North Carolina at Chapel Hill   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiviral resistance; Coronavirus; MERS CoV; Nucleoside analogue; Pandemic; RdRp; RNA dependent RNA polymerase; SARS CoV

Indexed keywords

ANTIVIRUS AGENT; BETA DEXTRO N4 HYDROXYCYTIDINE; EXORIBONUCLEASE; UNCLASSIFIED DRUG; CYTIDINE; N(4)-HYDROXYCYTIDINE; NSP14 PROTEIN, SARS CORONAVIRUS; RNA DIRECTED RNA POLYMERASE; VIRAL PROTEIN;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; EC50; ENZYME ACTIVITY; ENZYME INHIBITION; HIGH THROUGHPUT SEQUENCING; LIMIT OF QUANTITATION; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MOUSE; MURINE HEPATITIS VIRUS; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION; ANIMAL; CELL LINE; CHLOROCEBUS AETHIOPS; CORONAVIRIDAE INFECTION; CORONAVIRUS INFECTION; DRUG EFFECT; GENETICS; METABOLISM; MUTAGENESIS; TUMOR CELL LINE; VERO CELL LINE; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CELL LINE, TUMOR; CHLOROCEBUS AETHIOPS; CORONAVIRIDAE INFECTIONS; CORONAVIRUS INFECTIONS; CYTIDINE; DRUG RESISTANCE, VIRAL; EXORIBONUCLEASES; MICE; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MURINE HEPATITIS VIRUS; MUTAGENESIS; RNA REPLICASE; VERO CELLS; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 85075814794     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01348-19     Document Type: Article

References (74)

1. Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, Tong S, Urbani C, Comer JA, Lim W, Rollin PE, Dowell SF, Ling A-E, Humphrey CD, Shieh W-J, Guarner J, Paddock CD, Rota P, Fields B, DeRisi J, Yang J-Y, Cox N, Hughes JM, DeLuc JW, Bellini WJ, Anderson LJ. 2003. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 348:1953-1966. https://doi.org/10.1056/NEJMoa030781.
2. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus A, Fouchier R. 2012. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367:1814-1820. https://doi.org/10.1056/NEJMoa1211721.
3. Nassar MS, Bakrebah MA, Meo SA, Alsuabeyl MS, Zaher WA. 2018. Global seasonal occurrence of Middle East respiratory syndrome coronavirus (MERS-CoV) infection. Eur Rev Med Pharmacol Sci 22:3913-3918. https://doi.org/10.26355/eurrev_201806_15276.
4. McIntosh K, Kapikian AZ, Turner HC, Hartley JW, Parrott RH, Chanock RM. 1970. Seroepidemiologic studies of coronavirus infection in adults and children. Am J Epidemiol 91:585-592. https://doi.org/10.1093/oxfordjournals.aje.a121171.
5. Gaunt ER, Hardie A, Claas ECJ, Simmonds P, Templeton KE. 2010. Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method. J Clin Microbiol 48:2940 -2947. https://doi.org/10.1128/JCM.00636-10.
6. Walsh EE, Shin JH, Falsey AR. 2013. Clinical impact of human coronaviruses 229E and OC43 infection in diverse adult populations. J Infect Dis 208:1634 -1642. https://doi.org/10.1093/infdis/jit393.
7. Menachery VD, Yount BL, Debbink K, Agnihothram S, Gralinski LE, Plante JA, Graham RL, Scobey T, Ge X-Y, Donaldson EF, Randell SH, Lanzavecchia A, Marasco WA, Shi Z-L, Baric RS. 2015. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat Med 21:1508 -1513. https://doi.org/10.1038/nm.3985.
8. Menachery VD, Yount BL, Jr, Sims AC, Debbink K, Agnihothram SS, Gralinski LE, Graham RL, Scobey T, Plante JA, Royal SR, Swanstrom J, Sheahan TP, Pickles RJ, Corti D, Randell SH, Lanzavecchia A, Marasco WA, Baric RS. 2016. SARS-like WIV1-CoV poised for human emer- gence. Proc Natl Acad Sci U S A 113:3048 -3053. https://doi.org/10.1073/pnas.1517719113.
9. Anthony SJ, Gilardi K, Menachery VD, Goldstein T, Ssebide B, Mbabazi R, Navarrete-Macias I, Liang E, Wells H, Hicks A, Petrosov A, Byarugaba DK, Debbink K, Dinnon KH, Scobey T, Randell SH, Yount BL, Cranfield M, Johnson CK, Baric RS, Lipkin WI, Mazet J. 2017. Further evidence for bats as the evolutionary source of Middle East respiratory syndrome coronavirus. mBio 8:e00373-17. https://doi.org/10.1128/mBio.00373-17.
10. Yang Y, Du L, Liu C, Wang L, Ma C, Tang J, Baric RS, Jiang S, Li F. 2014. Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus. Proc Natl Acad Sci U S A 111:12516-12521. https://doi.org/10.1073/pnas.1405889111.
11. Twu S-J, Chen T-J, Chen C-J, Olsen SJ, Lee L-T, Fisk T, Hsu K-H, Chang S-C, Chen K-T, Chiang I-H, Wu Y-C, Wu J-S, Dowell SF. 2003. Control measures for severe acute respiratory syndrome (SARS) in Taiwan. Emerg Infect Dis 9:718 -720. https://doi.org/10.3201/eid0906.030283.
12. Balkhy HH, Alenazi TH, Alshamrani MM, Baffoe-Bonnie H, Arabi Y, Hijazi R, Al-Abdely HM, El-Saed A, Johani Al S, Assiri AM, bin Saeed A. 2016. Description of a hospital outbreak of Middle East respiratory syndrome in a large tertiary care hospital in Saudi Arabia. Infect Control Hosp Epidemiol 37:1147-1155. https://doi.org/10.1017/ice.2016.132.
13. Park GE, Ko J-H, Peck KR, Lee JY, Lee JY, Cho SY, Ha YE, Kang C-I, Kang J-M, Kim Y-J, Huh HJ, Ki C-S, Lee NY, Lee JH, Jo IJ, Jeong B-H, Suh GY, Park J, Chung CR, Song J-H, Chung DR. 2016. Control of an outbreak of Middle East respiratory syndrome in a tertiary hospital in Korea. Ann Intern Med 165:87- 88. https://doi.org/10.7326/M15-2495.
14. Cheng VCC, Chan JFW, To KKW, Yuen KY. 2013. Clinical management and infection control of SARS: Lessons learned. Antiviral Res 100: 407-419. https://doi.org/10.1016/j.antiviral.2013.08.016.
15. Stockman LJ, Bellamy R, Garner P. 2006. SARS: Systematic review of treatment effects. PLoS Med 3:e343. https://doi.org/10.1371/journal.pmed.0030343.
16. Arabi Y, Shalhoub S, Mandourah Y, Al-Hameed F, Al-Omari A, Qasim Al E, Jose J, Alraddadi B, Almotairi A, Khatib Al K, Abdulmomen A, Qushmaq I, Sindi AA, Mady A, Solaiman O, Al-Raddadi R, Maghrabi K, Ragab A, Mekhlafi Al GA, Balkhy HH, Harthy Al A, Kharaba A, Gramish JA, Al-Aithan AM, Al-Dawood A, Merson L, Hayden FG, Fowler R, Saudi Critical Care Trials Group. 25 June 2019. Ribavirin and interferon therapy for critically ill patients with the Middle East respiratory syndrome: A multicenter observational study. Clin Infect Dis https://doi.org/10.1093/cid/ciz544.
17. De Clercq E. 2006. Potential antivirals and antiviral strategies against SARS coronavirus infections. Expert Rev Anti Infect Ther 4:291-302. https://doi.org/10.1586/14787210.4.2.291.
18. Zumla A, Chan JFW, Azhar EI, Hui DSC, Yuen K-Y. 2016. Coronaviruses- drug discovery and therapeutic options. Nat Rev Drug Discov 15: 327-347. https://doi.org/10.1038/nrd.2015.37.
19. Adedeji AO, Sarafianos SG. 2014. Antiviral drugs specific for coronaviruses in preclinical development. Curr Opin Virol 8:45-53. https://doi.org/10.1016/j.coviro.2014.06.002.
20. Clercq ED. 2004. Antivirals and antiviral strategies. Nat Rev Microbiol 2:704 -720. https://doi.org/10.1038/nrmicro975.
21. De Clercq E, Li G. 2016. Approved antiviral drugs over the past 50 years. Clin Microbiol Rev 29:695-747. https://doi.org/10.1128/CMR.00102-15.
22. Jordheim LP, Durantel D, Zoulim F, Dumontet C. 2013. Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat Rev Drug Discov 12:447- 464. https://doi.org/10.1038/nrd4010.
23. Deval J. 2009. Antimicrobial strategies. Drugs 69:151-166. https://doi.org/10.2165/00003495-200969020-00002.
24. Mahmoud S, Hasabelnaby S, Hammad S, Sakr T. 2018. Antiviral nucleoside and nucleotide analogs: A review. J Adv Pharm Res 2:73- 88. https://doi.org/10.21608/aprh.2018.5829.
25. Eltahla A, Luciani F, White P, Lloyd A, Bull R. 2015. Inhibitors of the hepatitis C virus polymerase; mode of action and resistance. Viruses 7:5206 -5224. https://doi.org/10.3390/v7102868.
26. Smith EC, Blanc H, Surdel MC, Vignuzzi M, Denison MR. 2013. Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: Evidence for proofreading and potential therapeutics. PLoS Pathog 9:e1003565. https://doi.org/10.1371/journal.ppat.1003565.
27. Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL, Van Tongeren SA, Dong L, Retterer CJ, Eaton BP, Pegoraro G, Honnold S, Bantia S, Kotian P, Chen X, Taubenheim BR, Welch LS, Minning DM, Babu YS, Sheridan WP, Bavari S. 2014. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 508: 402-405. https://doi.org/10.1038/nature13027.
28. Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, Siegel D, Perron M, Bannister R, Hui HC, Larson N, Strickley R, Wells J, Stuthman KS, Van Tongeren SA, Garza NL, Donnelly G, Shurtleff AC, Retterer CJ, Gharaibeh D, Zamani R, Kenny T, Eaton BP, Grimes E, Welch LS, Gomba L, Wilhelmsen CL, Nichols DK, Nuss JE, Nagle ER, Kugelman JR, Palacios G, Doerffler E, Neville S, Carra E, Clarke MO, Zhang L, Lew W, Ross B, Wang Q, Chun K, Wolfe L, Babusis D, Park Y, Stray KM, Trancheva I, Feng JY, Barauskas O, Xu Y, Wong P, Braun MR, Flint M, McMullan LK, Chen S-S, Fearns R, Swaminathan S, Mayers DL, Spiropoulou CF, Lee WA, Nichol ST, Cihlar T, Bavari S. 2016. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 531:381-385. https://doi.org/10.1038/nature17180.
29. Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, Leist SR, Pyrc K, Feng JY, Trantcheva I, Bannister R, Park Y, Babusis D, Clarke MO, Mackman RL, Spahn JE, Palmiotti CA, Siegel D, Ray AS, Cihlar T, Jordan R, Denison MR, Baric RS. 2017. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 9:eaal3653. https://doi.org/10.1126/scitranslmed.aal3653.
30. Hofmann WP, Soriano V, Zeuzem S. 2009. Antiviral combination therapy for treatment of chronic hepatitis B, hepatitis C, and human immunodeficiency virus infection. Handb Exp Pharmacol 189:321-346. https://doi.org/10.1007/978-3-540-79086-0_12.
31. Urakova N, Kuznetsova V, Crossman DK, Sokratian A, Guthrie DB, Kolykhalov AA, Lockwood MA, Natchus MG, Crowley MR, Painter GR, Frolova EI, Frolov I. 2017. β-D-N(4)-Hydroxycytidine is a potent antialphavirus compound that induces high level of mutations in viral genome. J Virol 92:e01965-17. https://doi.org/10.1128/JVI.01965-17.
32. Ehteshami M, Tao S, Zandi K, Hsiao H-M, Jiang Y, Hammond E, Amblard F, Russell OO, Merits A, Schinazi RF. 2017. Characterization of β-D-N4-Hydroxycytidine as a novel inhibitor of chikungunya virus. Antimicrob Agents Chemother 61:e02395-16. https://doi.org/10.1128/AAC.02395-16.
33. Costantini VP, Whitaker T, Barclay L, Lee D, McBrayer TR, Schinazi RF, Vinje J. 2012. Antiviral activity of nucleoside analogues against norovirus. Antivir Ther 17:981-991. https://doi.org/10.3851/IMP2229.
34. Yoon J-J, Toots M, Lee S, Lee M-E, Ludeke B, Luczo JM, Ganti K, Cox RM, Sticher ZM, Edpuganti V, Mitchell DG, Lockwood MA, Kolykhalov AA, Greninger AL, Moore ML, Painter GR, Lowen AC, Tompkins SM, Fearns R, Natchus MG, Plemper RK. 2018. Orally efficacious broadspectrum ribonucleoside analog inhibitor of influenza and respiratory syncytial viruses. Antimicrob Agents Chemother 62:1427. https://doi.org/10.1128/AAC.00766-18.
35. Reynard O, Nguyen X-N, Alazard-Dany N, Barateau V, Cimarelli A, Volchkov VE. 2015. Identification of a new ribonucleoside inhibitor of Ebola virus replication. Viruses 7:6233-6240. https://doi.org/10.3390/v7122934.
36. Stuyver LJ, Whitaker T, McBrayer TR, Hernandez-Santiago BI, Lostia S, Tharnish PM, Ramesh M, Chu CK, Jordan R, Shi J, Rachakonda S, Watanabe KA, Otto MJ, Schinazi RF. 2003. Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture. Antimicrob Agents Chemother 47:244 -254. https://doi.org/10.1128/aac.47.1.244-254.2003.
37. Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, Smith EC, Case JB, Feng JY, Jordan R, Ray AS, Cihlar T, Siegel D, Mackman RL, Clarke MO, Baric RS, Denison MR. 2018. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio 9:1953. https://doi.org/10.1128/mBio.00221-18.
38. Graepel KW, Lu X, Case JB, Sexton NR, Smith EC, Denison MR. 2017. Proofreading-deficient coronaviruses adapt for increased fitness over long-term passage without reversion of exoribonuclease-inactivating mutations. mBio 8:e01503-17. https://doi.org/10.1128/mBio.01503-17.
39. Popowska E, Janion C. 1974. N4-hydroxycytidine-a new mutagen of a base analogue type. Biochem Biophys Res Commun 56:459-466. https://doi.org/10.1016/0006-291x(74)90864-x.
40. Daelemans D, Pauwels R, De Clercq E, Pannecouque C. 2011. A timeof-drug addition approach to target identification of antiviral compounds. Nat Protoc 6:925-933. https://doi.org/10.1038/nprot.2011.330.
41. Salganik RI, Vasjunina EA, Poslovina AS, Andreeva IS. 1973. Mutagenic action of N4-hydroxycytidine on Escherichia coli B cyt-. Mutat Res 20:1-5. https://doi.org/10.1016/0027-5107(73)90091-2.
42. Popowska E, Janion C. 1975. The metabolism of N4-hydroxycytidine-a mutagen for Salmonella typhimurium. Nucleic Acids Res 2:1143-1151. https://doi.org/10.1093/nar/2.7.1143.
43. Pyrc K, Bosch BJ, Berkhout B, Jebbink MF, Dijkman R, Rottier P, van der Hoek L. 2006. Inhibition of human coronavirus NL63 infection at early stages of the replication cycle. Antimicrob Agents Chemother 50: 2000-2008. https://doi.org/10.1128/AAC.01598-05.
44. Barnard DL, Hubbard VD, Burton J, Smee DF, Morrey JD, Otto MJ, Sidwell RW. 2004. Inhibition of severe acute respiratory syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and β-D-N4-hydroxycytidine. Antivir Chem Chemother 15:15-22. https://doi.org/10.1177/095632020401500102.
45. Sexton NR, Smith EC, Blanc H, Vignuzzi M, Peersen OB, Denison MR. 2016. Homology-based identification of a mutation in the coronavirus RNA-dependent RNA polymerase that confers resistance to multiple mutagens. J Virol 90:7415-7428. https://doi.org/10.1128/JVI.00080-16.
46. Ferron F, Subissi L, Silveira De Morais AT, Le NTT, Sevajol M, Gluais L, Decroly E, Vonrhein C, Bricogne G, Canard B, Imbert I. 2017. Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA. Proc Natl Acad Sci U S A 115:E162-E179. https://doi.org/10.1073/pnas.1718806115.
47. Derse D, Cheng Y-C, Furman PA, Clair MHS, Elion GB. 1981. Inhibition of purified human and herpes simplex virus-induced DNA polymerases by 9-(2-hydroxyethoxymethyl)guanine triphosphate. J Biol Chem 256: 11447-11451.
48. Chamberlain JM, Sortino K, Sethna P, Bae A, Lanier R, Bambara RA, Dewhurst S. 2019. Cidofovir diphosphate inhibits adenovirus 5 DNA polymerase via both nonobligate chain termination and direct inhibition, and polymerase mutations confer cidofovir resistance on intact virus. Antimicrob Agents Chemother 63:331. https://doi.org/10.1128/AAC.01925-18.
49. Śledziewska-Gojska E, Janion C. 1982. Effect of proofreading and dam-instructed mismatch repair systems on N4-hydroxycytidineinduced mutagenesis. Mol Gen Genet 186:411- 418. https://doi.org/10.1007/BF00729462.
50. Bouvet M, Imbert I, Subissi L, Gluais L, Canard B, Decroly E. 2012. RNA 3=-end mismatch excision by the severe acute respiratory syndrome coronavirus nonstructural protein nsp10/nsp14 exoribonuclease complex. Proc Natl Acad Sci U S A 109:9372-9377. https://doi.org/10.1073/pnas.1201130109.
51. Tejero H, Montero F, Nuno JC. 2016. Theories of lethal mutagenesis: From error catastrophe to lethal defection. Curr Top Microbiol Immunol 392: 161-179. https://doi.org/10.1007/82_2015_463.
52. Biktasova A, Hajek M, Sewell A, Gary C, Bellinger G, Deshpande HA, Bhatia A, Burtness B, Judson B, Mehra S, Yarbrough WG, Issaeva N. 2017. Demethylation therapy as a targeted treatment for human papillomavirus-associated head and neck cancer. Clin Cancer Res 23: 7276-7287. https://doi.org/10.1158/1078-0432.CCR-17-1438.
53. Leyssen P, Balzarini J, De Clercq E, Neyts J. 2005. The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J Virol 79:1943-1947. https://doi.org/10.1128/JVI.79.3.1943 -1947.2005.
54. Sanjuan R, Nebot MR, Chirico N, Mansky LM, Belshaw R. 2010. Viral mutation rates. J Virol 84:9733-9748. https://doi.org/10.1128/JVI.00694-10.
55. Hemida MG, Chu DKW, Poon LLM, Perera R, Alhammadi MA, Ng H-Y, Siu LY, Guan Y, Alnaeem A, Peiris M. 2014. MERS coronavirus in dromedary camel herd, Saudi Arabia. Emerg Infect Dis 20:1231-1234. https://doi.org/10.3201/eid2007.140571.
56. Cotten M, Watson SJ, Zumla AI, Makhdoom HQ, Palser AL, Ong SH, Al Rabeeah AA, Alhakeem RF, Assiri A, Al-Tawfiq JA, Albarrak A, Barry M, Shibl A, Alrabiah FA, Hajjar S, Balkhy HH, Flemban H, Rambaut A, Kellam P, Memish ZA. 2014. Spread, circulation, and evolution of the Middle East respiratory syndrome coronavirus. mBio 5:1814. https://doi.org/10.1128/mBio.01062-13.
57. Domingo E, Sheldon J, Perales C. 2012. Viral quasispecies evolution. Microbiol Mol Biol Rev 76:159 -216. https://doi.org/10.1128/MMBR.05023-11.
58. Bloom JD, Lu Z, Chen D, Raval A, Venturelli OS, Arnold FH. 2007. Evolution favors protein mutational robustness in sufficiently large populations. BMC Biol 5:29 -21. https://doi.org/10.1186/1741-7007-5-29.
59. Fares MA. 2015. The origins of mutational robustness. Trends Genet 31:373-381. https://doi.org/10.1016/j.tig.2015.04.008.
60. Schwarz B, Routledge E, Siddell SG. 1990. Murine coronavirus nonstructural protein ns2 is not essential for virus replication in transformed cells. J Virol 64:4784-4791.
61. Zhao L, Rose KM, Elliott R, Van Rooijen N, Weiss SR. 2011. Cell-typespecific type I interferon antagonism influences organ tropism of murine coronavirus. J Virol 85:10058 -10068. https://doi.org/10.1128/JVI.05075-11.
62. Graham RL, Sims AC, Brockway SM, Baric RS, Denison MR. 2005. The nsp2 replicase proteins of murine hepatitis virus and severe acute respiratory syndrome coronavirus are dispensable for viral replication. J Virol 79: 13399-13411. https://doi.org/10.1128/JVI.79.21.13399-13411.2005.
63. Manrubia SC, Domingo E, Lazaro E. 2010. Pathways to extinction: Beyond the error threshold. Philos Trans R Soc B Biol Sci 365:1943-1952. https://doi.org/10.1098/rstb.2010.0076.
64. Sanjuan R, Moya A, Elena SF. 2004. The contribution of epistasis to the architecture of fitness in an RNA virus. Proc Natl Acad Sci U S A 101:15376-15379. https://doi.org/10.1073/pnas.0404125101.
65. Lyons D, Lauring A. 2018. Mutation and epistasis in influenza virus evolution. Viruses 10:E407. https://doi.org/10.3390/v10080407.
66. Chen W, Baric RS. 1996. Molecular anatomy of mouse hepatitis virus persistence: Coevolution of increased host cell resistance and virus virulence. J Virol 70:3947-3960.
67. Yount B, Denison MR, Weiss SR, Baric RS. 2002. Systematic assembly of a full-length infectious cDNA of mouse hepatitis virus strain A59. J Virol 76:11065-11078. https://doi.org/10.1128/jvi.76.21.11065-11078.2002.
68. Almazan F, Marquez-Jurado S, Nogales A, Enjuanes L. 2015. Engineering infectious cDNAs of coronavirus as bacterial artificial chromosomes. Methods Mol Biol 1282:135-152. https://doi.org/10.1007/978-1-4939 -2438-7_13.
69. Eckerle LD, Lu X, Sperry SM, Choi L, Denison MR. 2007. High fidelity of murine hepatitis virus replication is decreased in nsp14 exoribonuclease mutants. J Virol 81:12135-12144. https://doi.org/10.1128/JVI.01296-07.
70. Coleman CM, Frieman MB. 2015. Growth and quantification of MERSCoV infection. Curr Protoc Microbiol 37:15E.2.1-9. https://doi.org/10.1002/9780471729259.mc15e02s37.
71. Bolger AM, Lohse M, Usadel B. 2014. Trimmomatic: A flexible trimmer for Illumina sequence data. Bioinformatics 30:2114 -2120. https://doi.org/10.1093/bioinformatics/btu170.
72. Langmead B, Wilks C, Antonescu V, Charles R. 2019. Scaling read aligners to hundreds of threads on general-purpose processors. Bioinformatics 35:421- 432. https://doi.org/10.1093/bioinformatics/bty648.
73. Wilm A, Aw PPK, Bertrand D, Yeo GHT, Ong SH, Wong CH, Khor CC, Petric R, Hibberd ML, Nagarajan N. 2012. LoFreq: A sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets. Nucleic Acids Res 40: 11189-11201. https://doi.org/10.1093/nar/gks918.
74. Nakamura K, Oshima T, Morimoto T, Ikeda S, Yoshikawa H, Shiwa Y, Ishikawa S, Linak MC, Hirai A, Takahashi H, Altaf-Ul-Amin M, Ogasawara N, Kanaya S. 2011. Sequence-specific error profile of Illumina sequencers. Nucleic Acids Res 39:e90. https://doi.org/10.1093/nar/gkr344.